A Dually Nanobody‐Engineered Milk‐Derived Extracellular Vesicle Nanomedicine Targeting Tumour‐Associated Macrophages and Cancer Cells for Cancer Therapy
Journal of Extracellular Vesicles · 2026
DOI: 10.1002/jev2.70236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2026. Verfasst von Zhiang Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Tumor-Associated Macrophages, Nanomedicine, Single-Domain Antibodies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Social Development Key Project of Jiangsu Province, Wuxi Medical Key Discipline, National Natural Science Foundation of China.
Abstract (Originalsprache)
Tumour development and progression are driven by intricate interactions among various cell types within the tumour microenvironment (TME). Targeting a single cell type often fails to eradicate cancer, highlighting the need for strategies to co‐target multiple cell types. MicroRNA‐21‐5p, highly abundant in tumour cells and tumour‐associated macrophages (TAMs), exerts strong cancer‐promoting effects. Epidermal growth factor receptor (EGFR) is overexpressed in various cancer types, and programmed death‐ligand 1 (PD‐L1) is expressed predominantly by TAMs in multiple cancers. In this study, we developed a dual‐targeted engineered milk‐derived extracellular vesicles system (7D12/KN035‐iEVs), decorated with 7D12 (an EGFR nanobody) and KN035 (a PD‐L1 nanobody), to specifically deliver miR‐21‐5p inhibitors into EGFR + and/or PD‐L1 + tumour cells and TAMs, thereby inhibiting tumour progression while reprogramming immunosuppressive TME. Notably, this dual‐targeting nanomedicine synergistically inhibits tumour growth when combined with immunotherapy and radiotherapy. In summary, this mEV‐based nanomedicine represents a promising universal strategy for cancer treatment, offering a versatile platform for targeting multiple components of the TME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
- Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China.
- Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, Jiangsu, China.
ORCID-Profile: Zehua Bian, Yuan Yin, Kaisa Cui, Zhimeng Wu, Zhaohui Huang
Förderung
- Social Development Key Project of Jiangsu Province
- Wuxi Medical Key Discipline
- National Natural Science Foundation of China
- Medical Key Strategic Project of Wuxi Health Commission
- Postgraduate Research & Practice Innovation Program of Jiangsu Province
- Key Industry Talents of "333" Projects of Jiangsu Province
Zitieren
APA
Liu, Z., Chen, Y., Cao, Y., Zhang, Y., Wang, Y., Cheng, H., Tang, J., Hong, H., Feng, Y., Yao, S., Bian, Z., Yin, Y., Cui, K., Wu, Z., & Huang, Z. (2026). A Dually Nanobody‐Engineered Milk‐Derived Extracellular Vesicle Nanomedicine Targeting Tumour‐Associated Macrophages and Cancer Cells for Cancer Therapy. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70236
Vancouver
Liu Z, Chen Y, Cao Y, Zhang Y, Wang Y, Cheng H, et al. A Dually Nanobody‐Engineered Milk‐Derived Extracellular Vesicle Nanomedicine Targeting Tumour‐Associated Macrophages and Cancer Cells for Cancer Therapy. Journal of Extracellular Vesicles. 2026. doi:10.1002/jev2.70236
BibTeX
@article{Liu2026,
author = {Liu, Zhiang and Chen, Ying and Cao, Yulin and Zhang, Yanchao and Wang, Yuanben and Cheng, Han and Tang, Junhui and Hong, Haofei and Feng, Yuyang and Yao, Surui and Bian, Zehua and Yin, Yuan and Cui, Kaisa and Wu, Zhimeng and Huang, Zhaohui},
title = {A Dually Nanobody‐Engineered Milk‐Derived Extracellular Vesicle Nanomedicine Targeting Tumour‐Associated Macrophages and Cancer Cells for Cancer Therapy},
journal = {Journal of Extracellular Vesicles},
year = {2026},
doi = {10.1002/jev2.70236}
}
EUVIMED